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a b s t r a c t
Hereditary renal amyloidosis is an autosomal dominant condition with considerable over-
lap with other amyloidosis types. Differential diagnosis is complicated, but is relevant for
prognosis and treatment. We describe a patient with nephrotic syndrome and progressive
renal failure, who had a mother with renal amyloidosis.
Renal biopsy revealed amyloid deposits in glomerular space, with absence of light chains
and protein AA. We suspected amyloidosis with ﬁbrinogen A alpha chain deposits, which is
the most frequent cause of hereditary amyloidosis in Europe, with a glomerular preferential
affectation. However, the genetic study showed a novel mutation in apolipoprotein AI. On
reviewing the biopsy of the patient’s mother similar glomerular deposits were found, but
there were signiﬁcant deposits in the renal medulla as well, which is typical in APO AI
amyloidosis. The diagnosis was conﬁrmed by immunohistochemistry.
Apo AI amyloidosis is characterised by slowly progressive renal disease and end-stage
renal disease occurs approximately 3–15 years from initial diagnosis. Renal transplanta-
tion offers an acceptable graft survival and in these patients with hepatorenal involvement
simultaneous liver and kidney transplantation could be considered.© 2015 The Authors. Published by Elsevier España, S.L.U. on behalf of Sociedad Española
de Nefrología. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Amiloidosis renal hereditaria por depósito de apolipoproteína AI: un reto
diagnóstico
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r e s u m e n
La amiloidoisis renal hereditaria es un trastorno autosómico dominante cuya clínica se
solapa con la de otros tipos de amiloidoisis. Hacer un adecuado diagnóstico diferencial
puede ser difícil, pero tiene una gran relevancia respecto al pronóstico y tratamiento, que
diﬁere según sea el origen de la enfermedad. Presentamos el caso clínico de un paciente
con síndrome nefrótico e insuﬁciencia renal progresiva, con antecedente familiar de
madre con amiloidosis renal.
En la biopsia renal se observó depósito de amiloide a nivel glomerular, con negatividad
para cadenas ligeras y proteína AA. La sospecha clínica inicial fue la de amiloidosis por
depósito de cadena A alfa de ﬁbrinógeno, que es la causa más frecuente de amiloidosis
hereditaria en Europa, con afectación preferentemente glomerular. Sin embargo, el estudio
genético determinó una nueva mutación previamente no descrita de la Apolipoproteina AI
(APO AI). En la biopsia de la madre se detectó depósito glomerular, pero también depósito
masivo en médula, lo que caracteriza a la amiloidosis por depósito de APO AI. El diagnóstico
se conﬁrmó mediante inmunohistoquímica.
La amiloidosis por depósito de Apo AI progresa a enfermedad renal crónica terminal en
el plazo de de 3 a 15 an˜os. Se diferencia clínicamente de la amiloidosis AL por su menor
afectación extrarrenal y su mejor pronóstico. El trasplante renal ofrece una supervivencia
del injerto aceptable y el trasplante hepato-renal se podría tener en cuenta en pacientes con
disfunción signiﬁcativa de ambos órganos.
© 2015 The Authors. Publicado por Elsevier España, S.L.U. en nombre de Sociedad Española
de Nefrología. Este es un artículo Open Access bajo la licencia CC BY-NC-ND
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40-year-old male came to the emergency room complaining
f oedemas. Patient presented family history of mother with
on-afﬁliated renal amyloidosis. The mother’s renal biopsy
howed permanganate resistance, which seemed to rule out
A amyloidosis, and led to consider the possibility of AL amy-
oidosis.
Thepatient didnot receive anypharmacological treatment.
pon physical examination, the patient presented blood pres-
ure of 135/75mmHg and bimalleolar oedemas, without other
ata of interest. Laboratory tests conﬁrmed the presence of
ephrotic syndrome (serum albumin of 2.5 g/dl, cholestero-
aemia of 275mg/dl and urine protein of 6 g/24h), without
lterations in the sediment and with normal glomerular ﬁl-
ration rate. Electrophoretic spectrum in blood and urine,
mmunological study and renal ultrasound scan were normal.
renal biopsy was performed that presented 19 glomeruli
ith fully distorted structure by a hyaline deposit in nodu-
ar disposition, with positivity for Congo red and thioﬂavin.
ubules and vessels did not show signiﬁcant alterations and
herefore the ﬁndings were compatible with amyloidosis. The
tudy of a parafﬁn sample showed a marked positivity for
P protein, which is a part of the amyloid substance com-
on in all amyloidosis types, with negativity for light chainsnd AA protein, B2 microglobulin and transthyretin. A supple-
entary study was performed with antibodies to ﬁbrinogen
nd lysozyme and the amyloid substance deposits resulted(http://creativecommons.org/licenses/by-nc-nd/4.0/).
positive for the ﬁbrinogen A-alpha chain (AFib). However,
the genetic study did not show any mutation in the AFib
chain gene but there was a previously undescribed muta-
tion in the Apolipoprotein A1 gene (Apo AI). Faced with this
discrepancy, the mother’s biopsy was analysed. The biopsy
contained a glomerular deposit in the cortex and a massive
deposit at the medullary level. The deposit at the medullary
level was not described in the AFib amyloidosis, being very
characteristic of the Apo AI. The conclusion is that the ﬁrst
results of the immunohistochemistry were not completely
reliable as it was not performed under adequate conditions.
The presence of Apo AI was later conﬁrmed using the same
technique.
An extension study was performed, with echocardio-
gram and electromyography, without signs of heart condition
or autonomic neuropathy. The clinical evolution showed a
progressive increase in transaminases, suggesting hepatic
involvement. These results were in agreement with this type
of familial amyloidosis which, preferably, involves the kid-
ney and liver. Although the intila GFR was normal, renal
function subsequently deteriorated progressively until renal
replacement therapy was required after 2 years. The patient
received treatment with peritoneal dialysis for 4 years, there-
after the patient underwent undergoing renal transplantation
from a deceased donor. The patient presented a complicated
postoperative period with splenic rupture, in the context of
his disease, with amyloid deposit in the spleen. An urgent
splenectomy was indicated. Finally, the patient was dis-
charged in stable condition (Figs. 1–4).
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Fig. 1 – (A) Renal biopsy (son). Cortical parenchyma with massive glomerular deposit of amyloid substance stained with
Congo red. (B) Renal biopsy (son). Cortical parenchyma with massive glomerular deposit of amyloid substance observed
ﬂam
Some of the published cases describe extensive visceralwith polarised light. There is also ﬁbrosis and interstitial in
Discussion
Hereditary non-neuropathic renal amyloidosis was ﬁrst
describedbyOstertag in 1932.1 Thisnamewasgiven to empha-
sise the absence of peripheral nervous system involvement,
with the purpose of differentiating this pathology from other
types of amyloidosis. However, this term is confusing and is
not currently appropriate because several variants related to
the apolipoprotein A1 associated with neuropathy have been
described since then.2 In regards to this disease, more than
25 mutations that alter the structure of different proteins,
causing the deposit in amyloid form, have been identiﬁed.
These proteins are lysozyme,3 Apo AI,4,5 Apolipoprotein A II
(Apo II)6,7 and AFib chain.8–12 Clinically, all of them manifest
themselves with renal failure at middle age and they have a
dominant autosomic heritage, although with highly variable
penetrance and somespeciﬁc clinic characteristics, depending
on the protein that originates the deposit.
Fig. 2 – Renal biopsy (son). Immunohistochemistry for Apo
AI, with intense positivity in glomerular deposits (×200).mation (×40).
Apo AI is the main protein that forms the high-density
lipoprotein (HDL) structure. It is secreted in the liver and
the small intestine and catabolised mainly in the liver
and kidneys.13–15 It is a co-factor for lecithin-cholesterol
acetyltransferase (LCAT), and its function is linked to choles-
terol elimination.13,15,16
To date, at least 19 amyloidogenic mutations have been
described in the APO AI gene. A different clinical presenta-
tion of the disease has been observed depending on the region
in which the mutation is located. In this way, mutations that
affect the amino-terminal region manifest themselves with
amyloid deposit at hepatic and renal level, whereas mutations
that affect the carboxi-terminal region manifest themselves
with cutaneous, laryngeal and cardiac amyloidosis.2,15,17
The Apo AI amyloidosis phenotype is very heterogeneous.amyloidosis and end-stage renal failure, whereas others
include larynx and skin involvement, with minimal clinical
Fig. 3 – Renal biopsy (mother). Massive glomerular deposit
in cortex (left) and interstitial deposit in bone marrow
(right) (Congo red ×100).
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Fig. 4 – (A) Renal biopsy (mother). Immunohistochemistry for positive Apo AI in glomerular deposits. (B) Renal biopsy
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cmother). Immunohistochemistry for positive Apo AI in rena
onsequences. Clinical expression does not only depend on
he mutation location, since even patients with the same
utationmay experience different clinical expression. Pheno-
ypic heterogeneity has also been observed between lineages
ith the sameApoAImutation. There are publications includ-
ng series of patients with an elevated number of relatives
ffected and fast progression to end-stage renal disease (10 out
f 16 cases affected),15 which suggests the existence of a more
ggressive phenotype or other genetic and environmental
actors interacting or having an inﬂuence on clinical mani-
estations. The possible amyloid deposit has been described
n several organs, among them the kidney, gastrointestinal
ract, spleen, liver, heart, peripheral nervous system, larynx
nd skin. The most common clinical presentation consists of
igh blood pressure, mild proteinuria and slowly progressive
enal failure deterioration between the ages of 18 and 55.
The ﬁrst mutation described, and the most frequent in
atientswithApoAI amyloidosis of Irish ancestry, is Gly26Arg.
t is characterised by the progressive accumulation of amy-
oid ﬁbrils composed by the amino-terminal polypeptide
ragments of the Apo AI and it appears in young patients,
ged 20–46. The amyloid deposit is located in the peripheral
erves, kidneys, liver and gastrointestinal tract,2,17 manifes-
ing itself clinically with peripheral neuropathy, peptic ulcer
nd nephropathy.2,18
At least up to 19 amyloidogenic mutations of Apo AI have
een described since. Here we describe a new mutation that
e did not ﬁnd in the literature, the c.220T>C (p.Trp74Arg).
n our patient’s case, we were able to observe kidney involve-
ent, with renal function impairment within two years, as
ell as liver and spleen involvement.
The histological analysis of Apo AI amyloidosis shows
redominant amyloid deposits at the medullary level with
ubulointerstitial nephritis pattern, characterised by tubular
trophy and interstitial ﬁbrosis, associated with secondary
ocal glomeruloesclerosis.15,19 Although interstitial involve-
ent is the most frequent, there are also cases in which
deposit at glomerular level has been detected.19–21 One
ase has even been published with predominant glomerulardulla interstitial deposits.
involvement, associated with nephrotic syndrome, as a result
of Apo AI Leu64Pro amyloidosis.22
The preferred selectiveness of Apo AI amyloidosis for the
renal medulla allows us to differentiate it from other types of
hereditary and acquired systemic amyloidosis,19,23 since this
preference for themedullary compartment is only sharedwith
transthyretin amyloidosis.19,24
In our case, the patient’s renal biopsy only contained cor-
tex and the glomerular compartment was the only place
where amyloid deposit was found. These ﬁndings are in agree-
ment with the clinical symptoms at diagnosis, consistent
nephrotic syndrome with posterior progressive worsening of
renal function. Initially, this particular characteristic made
us suspect ﬁbrinogen A alpha chain amyloidosis, since it
is the most frequent cause of hereditary renal amyloidosis
in Europe, and its deposit is characteristically glomerular.
However, the mother’s biopsy had glomerular deposit in cor-
tex, but it also had medulla with massive deposit. Finally,
the genetic study determined a new, previously undescribed,
Apo AI mutation, and the immunochemistry conﬁrmed the
diagnosis.
A correct differential diagnosis in systemic amyloidosis
is important since disease management and prognosis may
be completely different depending on its origin. This is the
reason why it is particularly relevant to determine the pro-
tein that originates the deposit. In accordance with a study
performed in the United Kingdom National Amyloidosis Cen-
tre, almost 10% of the patients with a presumptive diagnosis
of AL systemic amyloidosis actually suffer from a hereditary
amyloidosis.25 This usually happens because it is quite com-
mon to consider AL amyloidosis as a diagnosis of exclusion,
due to the clinical overlapping between different types of
amyloidosis, the relatively frequent ﬁnding of a monoclonal
protein in patients over 50, and the difﬁculty to determine the
type of ﬁbril, even when the AL amyloidosis diagnosis is cor-
rect, since in up to 20% of the cases the lambda or kappa light
chain antibodies are not bound to it, probably due to the alter-
ation in their structure. Moreover, it is not always possible to
verify the presence of family history of hereditary amyloidosis
015
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due to the variable penetrance of the disease and the diagnosis
of new mutations.
Among the methods available to determine the protein
composition of ﬁbrils, we ﬁnd immunochemistry and direct
protein sequencing. In order to perform this last technique, a
considerable amount of tissue is required which is not always
possible to obtain. The recent development of proteomic tech-
niques constitutes an advance in the diagnosis of amyloidosis
since in order to identify the protein that forms the amyloid
ﬁbril only a small amount of ﬁxed tissue is required.26
Regarding disease treatment, renal transplant due to Apo
AI amyloidosis has had varied success.19,27,28 There has been
recurrence of amyloidosis in grafts, but in most of the pub-
lished cases graft survival was acceptable. A study performed
in the United Kingdom National Amyloidosis Centre revealed
that out of 10 renal transplant recipients with APO AI amy-
loidosis, ﬁve showed documented evidence of amyloid deposit
in the transplanted kidney. However, only one patient, after
25 years, progressed to end-stage renal disease, initiating dial-
ysis again.21,29
Liver transplant is the ﬁnal treatment for other types of
hereditary amyloidosis, since the amyloidogenic protein is
synthesised in the liver. However, in the APO AI amyloid-
osis, the amyloidogenic protein is also synthesised in the
small intestine. Although there have been cases like that of an
Irish patient with the Apo AI Gly26Arg mutation, who under-
went hepatorenal transplant and two years later evidenced
a regression of the amyloid deposits,19,30 double hepatore-
nal transplant is only considered in patients with signiﬁcant
impairment in both organs.
In our patient’s case, we considered the best option was
renal transplant since hepatic function was not very impaired.
However, post-transplant evolution has become complicated
by splenic rupture due to amyloid deposit.
We could assert that hereditary renal amyloidosis consti-
tutes a diagnostic challenge due to the difﬁculty to identify the
protein that originates the deposit, and the importance of this
aspect in prognosis and treatment. In APO AI amyloidosis, the
indices cases diagnosis requires high clinical suspicion and
a renal medulla biopsy is important to observe the amyloid
deposit at this level. The possibility of this diagnosis has to be
considered in family cases of tubulointerstitial nephritis with
hepatic involvement.
Questions
1) Dr. Esther Rosello (Valencia). The diagnostic yield of amy-
loidosis often forces specialists to perform studies in fat,
rectal mucosa and, in the end, a renal biopsy. What is the
decision followed in the extraction of biopsies upon suspi-
cion of amyloidosis?
Answer (Kelly Samillán): Upon suspicion of amyloidosis,
the diagnosis can frequently be conﬁrmed through abdom-
inal fat aspiration, which is a mildly invasive technique.
The literature states that this technique provides high sen-
sitivity for the diagnosis of AL amyloidosis (between 80
and 90%) and a lower sensitivity (between 65 and 75%) for
AA amyloidosis diagnosis. However, in the case of famil-
ial amyloidosis, the diagnostic yield is very low and the;35(3):322–327
absence of positivity to Congo red in an abdominal fat
biopsy does not exclude the diagnosis.31 In regards to the
salivary gland and rectal mucosa biopsies, they are also
used as non-invasive diagnostic methods. We believe that
the diagnostic method in cases of amyloidosis must be
individualised in accordance with the patient’s character-
istics and comorbidity. In general, if a patient presents
apparent renal involvement, particularly if the patient has
nephrotic syndrome, our group indicates the performance
of a renal biopsy, except in the exceptional cases in which
the renal biopsy would not be decisive to take decisions or
in which the patient’s comorbidity does not allow it. In the
cases of Apo AI amyloidosis with renal involvement, in our
opinion, it is advisable to perform the renal biopsy directly.
2) Dr. Esther Roselló (Valencia). Do you think biopsy samples
could be sent to referral centers for special amyloidosis
techniques?
Answer (Manuel Solé): The diagnosis of amyloidosis
presents difﬁculties at two levels: the basic one, the diag-
nosis with Congo red stain, should be undertaken in the
centre itself, throughadequate technique control, although
we are aware of the many problems this poses. If typiﬁ-
cation is in question, it is important to use an antibodies
panel and the interpretation requires experience. In this
case, it would be adequate to refer the sample to an amy-
loidosis unit.
3) Dr. Miguel Ángel Martínez (Madrid): I would like to mention
that Congo red techniques are only successful if the cut
sessions have a minimum of 6m. Does that coincide with
your experience?
Answer (Manuel Solé): This is a very important technical
aspect. It is usually recommended to perform the stain on
8-m sections. However, this is not always possible, par-
ticularly in renal biopsies in which routine unstained cut
sections are performed for different techniques. If the cut
section is thin, the stain will be pale, but the green bire-
fringence will remain, although it may be more difﬁcult to
visualise.
4) Dr. Julia Blanco (Madrid). I have noticed that you have
obtained an excellent apple green in Congo red techniques,
do you have a secret formula?
Answer (Manuel Solé): It is essential that the observation
with polarised light be made with a powerful light source.
Not just any microscope will do. And remember that the
main feature of Congo red is dichroism, that is, the change
from red to golden and green when rotating the polarising
ﬁlter.
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